CTLA4 and uveitis: In Fang’s study, the anti-CTLA4, ipilimumab had the highest association with uveitis [28] but this finding was conflicting with that of Hou et al., who did not find excess risk for anti-CTLA-4 over anti-PD-1 [128] when looking at all-types ocular IRAEs.